Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
ERYTECH Granted U.S. FDA Fast Track Designation  for E ryaspase in Hypersensitive ALL Fast Track d esignation for eryaspase underscores the need for new treatment options for patients who developed hypersensitivity reactions to pegylated asparaginase Cambridge, MA (U.S.) and Lyon (France), July 29
View HTML
Toggle Summary ERYTECH to Participate in the BTIG Virtual Biotechnology Conference
ERYTECH to Participate in the BTIG Virtual Biotechnology Conference Cambridge, MA (U.S.) and Lyon (France) , Ju ly 2 7 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients
ERYTECH Confirms Plans To Submit BLA for E ryaspase in H ypersensitive ALL Patients M eeting with the U.S. FDA clarified steps and requirements for the submission of a Biologics License Application (BLA) for eryaspase for the treatment of ALL patients who developed hypersensitivity reactions to
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021
                 Monthly information related to total number of voting rights and shares composing the share capital – June 3 0 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Sep 21, 2021 at 8:30 AM EDT

Erytech Pharma 2nd Quarter of 2021 Conference Call and Webcast

A press release will be sent the day before.
Summary Toggle Nov 16, 2021 at 8:30 AM EST

Erytech Pharma 3rd Quarter of 2021 Conference Call and Webcast

A press release will be sent the day before.

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top